Medivir to present at the Redeye Life Science Day

Rhea-AI Summary

Medivir AB (MVIR) to Participate at Redeye Life Science Day; CEO to Discuss Latest Developments and Future Plans

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.

CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans. This will include, among other things, the company's proposed rights issue and how it aims to ensure the highest possible speed and momentum in the development program for fostrox with the aim of starting a pivotal phase 2b study in 2024.
 
The In Focus interview is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/915984/redeye-life-science-day-2023

For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3880410/2446356.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-life-science-day-301995674.html

SOURCE Medivir

FAQ

What event will Medivir AB participate in?

Medivir AB will participate in the Redeye Life Science Day, with CEO Jens Lindberg discussing the latest developments and future plans in an In Focus interview.

What is the focus of the In Focus interview at the event?

The focus of the In Focus interview will be on the latest developments, the company's future plans, and the proposed rights issue, with emphasis on the development program for fostrox and the aim of starting a pivotal phase 2b study in 2024.

What drug is Medivir AB focusing on in its development efforts?

Medivir AB is focusing on the development of fostrox, a pro-drug designed to selectively treat liver cancer cells and minimize side effects.

What is the current status of Medivir AB's share listing?

Medivir AB's share (MVIR) is listed on Nasdaq Stockholm's Small Cap list.

What is the primary focus of Medivir AB's drug candidates?

Medivir AB's drug candidates are directed toward indication areas where available therapies are limited or missing, with a focus on cancer and high unmet medical needs.